

Sheet 1 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED) U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary) (37 C.F.R. § 1.98(b))	Attorney Docket No.	50318/012001
	Serial No.	10/577,974
	Applicant	Barbara Ensoli et al.
	Filing Date	May 3, 2006
	Group	Not yet assigned
	IDS Filed	September 21, 2006

U.S. PATENT DOCUMENTS						
Examiner's Initials	Document Number	Publication Date	Patentee or Applicant	Class	Subclass	Filing Date (If Appropriate)
	4,415,700	11/15/83	Batz et al.			
	5,334,394	08/02/94	Kossovsky et al.			
	2004/0062815	04/01/04	Fricker et al.			

FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

Examiner's Initials	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation (Yes/No)
	DE 30 48 883	07/15/82	DE English equivalent only /nkW/			
	DE 101 18 852	10/31/02	DE English equivalent only /nkW/			
	EP 0 240 424	03/27/87	EP English abstract only /nkW/			
	WO 95/26376	10/05/95	WIPO			
	WO 00/12065	03/09/00	WIPO			

OTHER DOCUMENTS (INCLUDING AUTHOR, TITLE, DATE, PLACE OF PUBLICATION)

	Alpar et al., "New Strategies in Vaccine Delivery," S.T.P. Pharma. Sci. 10:269-278, 2000.
	Betti et al., "Characterization of HIV-1 Tat Proteins Mutated in the Transactivation Domain for Prophylactic and Therapeutic Application," Vaccine 19:3408-3419, 2001.
	Caputo et al., "Immunization with Low Doses of HIV-1 tat DNA Delivered by Novel Cationic Block Copolymers Induces CTL Responses Against Tat," Vaccine 21:1103-1111, 2003.
	Caputo et al., "Novel Biocompatible Anionic Polymeric Microspheres for the Delivery of the HIV-1 Tat Protein for Vaccine Application," Vaccine 22:2910-2924, 2004.
	Caselli et al., "DNA Immunization with HIV-1 tat Mutated in the trans Activation Domain Induces Humoral and Cellular Immune Responses Against Wild-Type Tat," J. Immunol. 162:5631-5638, 1999.
	Chang et al., "HIV-1 Tat Protein Exits from Cells Via a Leaderless Secretory Pathway and Binds to Extracellular Matrix-Associated Heparan Sulfate Proteoglycans Through its Basic Region," Aids 11:1421-1431, 1997.
	Dinnella et al., "Immobilization and Reactivity of Enzymes on Functional Particles Prepared by Dispersion Polymerization," Macromol. Rapid Commun. 15:909-915, 1994.

EXAMINER	/Nicole Kinsey/	DATE CONSIDERED	07/09/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NK/

Sheet 2 of 2

SUBSTITUTE FORM PTO-1449 (MODIFIED)	U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE	Attorney Docket No.	50318/012001
		Serial No.	10/577,974
		Applicant	Barbara Ensoli et al.
		Filing Date	May 3, 2006
		Group	Not yet assigned
		IDS Filed	September 21, 2006
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			
(37 C.F.R. § 1.98(b))			

	Ensoli et al., "Release, Uptake, and Effects of Extracellular Human Immunodeficiency Virus Type 1 Tat Protein on Cell Growth and Viral Transactivation," J. Virol. 67:277-287, 1993.
	Ensoli et al., "Synergy Between Basic Fibroblast Growth Factor and HIV-1 Tat Protein in Induction of Kaposi's Sarcoma," Nature 371:674-680, 1994.
	Fanales-Belasio et al., "Native HIV-1 Tat Protein Targets Monocyte-Derived Dendritic Cells and Enhances Their Maturation, Function, and Antigen-Specific T Cell Responses," J. Immunol. 168:197-206, 2002.
	Laus et al., "Microspheres with Hydrophilic and Protein-Friendly Surface as Protein Delivery Systems Prepared by Dispersion Polymerization," J. Controlled Release 72:225-309, 2001.
	Micheletti et al., "Identification of Cytotoxic T Lymphocyte Epitopes of Human Herpesvirus 8," Immunol. 106:395-403, 2002.
	Nedrud et al., "Adjuvants and the Mucosal Immune System," in <u>Topics in Vaccine Adjuvant Research</u> , CRC 51-67, 1991.
	Nugent et al., "Design and Delivery of Non-Parenteral Vaccines," J. Clin. Pharm. Therap. 23:257-285, 1998.
	O'Hagan et al., "Poly(lactide-co-glycolide) Microparticles for the Development of Single-Dose Controlled-Release Vaccines," Adv. Drug Deliv. Rev. 32:225-246, 1998.
	O'Hagan, "Recent Advances in Vaccine Adjuvants for Systemic and Mucosal Administration," J. Pharm. Pharmacol. 49:1-10, 1997.
	Sparnacci et al., "Core-Shell Microspheres by Dispersion Polymerization as Drug Delivery Systems," Macromol. Chem. Phys. 203:1364-1369, 2002.

EXAMINER	/Nicole Kinsey/	DATE CONSIDERED	07/09/2008
EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with the next communication to applicant.			

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /NK/